New combo tackles Drug-Resistant lung cancer

NCT ID NCT02503722

First seen Jan 09, 2026 · Last updated Apr 24, 2026 · Updated 24 times

Summary

This early-phase trial tests a new two-drug combination (sapanisertib plus osimertinib) in about 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goal is to find the safest dose and identify side effects. This is not a cure, but aims to control the disease by blocking key growth signals in cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Smilow Cancer Center/Yale-New Haven Hospital

    New Haven, Connecticut, 06510, United States

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.